Mannatech (NASDAQ:MTEX) and BeOne Medicines (NASDAQ:ONC) Head to Head Survey

Mannatech (NASDAQ:MTEX) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for Mannatech and BeOne Medicines, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1	0	0	0	1.00
BeOne Medicines	1	1	13	0	2.80

BeOne Medicines has a consensus target price of $378.43, indicating a potential upside of 8.12%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Mannatech.

Insider & Institutional Ownership

13.0% of Mannatech shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 41.5% of Mannatech shares are held by company insiders. Comparatively, 6.6% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Mannatech and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	-1.50%	-22.75%	-4.75%
BeOne Medicines	1.38%	5.52%	3.17%

Volatility and Risk

Mannatech has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Earnings and Valuation

This table compares Mannatech and BeOne Medicines”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$117.87 million	0.12	$2.49 million	($0.86)	-8.73
BeOne Medicines	$3.81 billion	10.07	-$644.79 million	$0.51	686.27

Mannatech has higher earnings, but lower revenue than BeOne Medicines. Mannatech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Summary

BeOne Medicines beats Mannatech on 11 of the 14 factors compared between the two stocks.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.